The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
350 jobs Number of planned job losses
Announcement Date
20 February 2004
Employment effect (start)
1 January 2004
Foreseen end date
1 December 2004
Description
Diosynth, Akzo Nobel's pharmaceutical ingredients manufacturing business, has announced a restructuring across the world. To face the declining demand, Diosynth is reducing its worldwide chemical synthesis capacity by closing its site in Mexico and scaling back facilities in the Netherlands. A start was already made last month with a reduction of production capacity at Buckhaven (Scotland) site. Workforce reductions will directly affect a total of approximately 350 employees. Closure of the site in Mexico City will affect all its 175 employees. The workforce in the Netherlands will be reduced by 100 employees in the course of 2004 through natural attrition and expiry of the majority of temporary employment contracts. In Buckhaven the workforce will be reduced by 75 people. For each site, consultation involving unions and works councils is being, or will be, undertaken as appropriate.
Sources
20 February 2004: Akzo Nobel - Press releases
20 February 2004: Het Financieele Dagblad
Citation
Eurofound (2004), Akzo Nobel, Internal restructuring in World, factsheet number 59351, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/59351.